15 To 23 Amino Acid Residues In Defined Sequence Patents (Class 530/326)
-
Patent number: 8906845Abstract: The disclosure provides peptide compounds that regulate the complement system and methods of using these compounds. Specifically the disclosure provides an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The peptide compounds disclosed include peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and/or substitutions, deletions and/or substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The disclosure further provides pharmaceutical compositions comprising therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.Type: GrantFiled: July 21, 2011Date of Patent: December 9, 2014Assignee: Eastern Virginia Medical SchoolInventors: Neel K. Krishna, Kenji M. Cunnion
-
Patent number: 8907055Abstract: There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.Type: GrantFiled: November 4, 2010Date of Patent: December 9, 2014Assignee: Agency for Science, Technology and ResearchInventors: Prasanna R. Kolatkar, Irene Aksoy, Ralf Jauch, Lawrence W. Stanton
-
Patent number: 8906844Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.Type: GrantFiled: August 1, 2008Date of Patent: December 9, 2014Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell
-
Patent number: 8906865Abstract: This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs, or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction or levels of inflammatory mediators.Type: GrantFiled: March 25, 2008Date of Patent: December 9, 2014Assignee: ISIS Innovation LimitedInventors: David R. Greaves, Andreas Russ, Jenna L. Cash
-
Patent number: 8907054Abstract: Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to radial spoke protein 3 (RSP3) or absent, small, homeotic discs 2-like protein (Ash2L) and that bind to Dumpy-30 protein (Dpy-30).Type: GrantFiled: August 8, 2012Date of Patent: December 9, 2014Assignee: Marquette UniversityInventors: Pinfen Yang, Priyanka Sivadas
-
Publication number: 20140356284Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.Type: ApplicationFiled: February 10, 2012Publication date: December 4, 2014Inventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn, Thomas Müller, Vasileios Askoxylakis
-
Publication number: 20140356409Abstract: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.Type: ApplicationFiled: December 21, 2012Publication date: December 4, 2014Inventor: Patrick M. Schlievert
-
Publication number: 20140357520Abstract: The present invention relates to novel peptides that may be used in whole or in combination for the detection of Mycobacterium tuberculosis infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from M. tuberculosis or vaccination using an epitope specific inoculation. More particularly, the present invention provides a means to distinguish early, active, and latent M. tuberculosis infection. More particularly, the present invention describes an immunological diagnostic mechanism for the detection of M. tuberculosis infection.Type: ApplicationFiled: February 7, 2013Publication date: December 4, 2014Inventor: Kimberly Luke
-
Publication number: 20140357512Abstract: The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker peptides, which are acetylated, for multiple myeloma. Alternatively, the biomarkers are drug specific, HDAC6 biomarker peptides, which are acetylated or unacetylated, for multiple myeloma. The invention also relates to a kit comprising a detection agent and instructions for identifying a biomarker peptide of the invention. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.Type: ApplicationFiled: June 3, 2014Publication date: December 4, 2014Applicant: ACETYLON PHARMACEUTICALS, INC.Inventors: Min Yang, Simon S. Jones
-
Publication number: 20140356320Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.Type: ApplicationFiled: July 23, 2012Publication date: December 4, 2014Applicant: Universität ZürichInventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
-
Publication number: 20140356418Abstract: Compositions useful for the prevention and/or treatment of Alzheimer's disease are disclosed. The composition comprises carrier particles each linked to a plurality of peptide constructs comprising a peptide binding sequence capable of binding to an amyloid protein and a transit amino acid sequence linked to said binding sequence. The binding sequence may be retroinverted D-peptide mimetic of an L-peptide binding sequence and the transit sequence may be a D-peptide mimetic of an L-peptide transit sequence (e.g. TAT) The preferred peptide construct comprises the sequence rGffvlkGrrrrqrrkkrGy. The preferred carrier particles are liposomes.Type: ApplicationFiled: October 10, 2012Publication date: December 4, 2014Inventors: Mark Neville Taylor, David Allsop
-
Patent number: 8900880Abstract: The present invention relates to an antigenically effective peptide comprising, from the amino to the carboxylic terminal, the amino acid sequence: G P P W W P P I C D P P Q P S K T Q G Q S X1 G Q S X2 G X3 G X4 G X5 G X6 G X7 G K G K S X8 D K Q X9 K P G G P W X10 P E P (SEQ ID No. 1), wherein the amino acids X1-X10 are selected independently from an arginine residue or a citrulline residue and at least one of X1-X10 is a citrulline residue, or a functional fragment thereof and uses thereof.Type: GrantFiled: November 22, 2010Date of Patent: December 2, 2014Assignee: Toscana Biomarkers S.R.L.Inventors: Paola Migliorini, Federico Pratesi
-
Publication number: 20140349917Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.Type: ApplicationFiled: April 17, 2014Publication date: November 27, 2014Applicant: C3 JIAN, INC.Inventors: RANDAL H. ECKERT, CHRIS KAPLAN, JIAN HE, DANIEL K. YARBROUGH, MAXWELL ANDERSON, JEE-HYUN SIM
-
Publication number: 20140348902Abstract: Provided are TCL1 peptides that bind to MHC I (HLA-A2) on tumor cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The TCL1 peptides may be therapeutically used to treat a cancer, such as a B cell malignancy, leukemia, or lymphoma. Methods for expanding a population of T cells that target TCL1 are also provided.Type: ApplicationFiled: November 19, 2012Publication date: November 27, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Sattva S. Neelapu, Jinsheng Weng
-
Publication number: 20140348861Abstract: Synthetic peptides and peptide copolymers for amelioration of autoimmune neurological syndrome, inflammatory and/or demyelinating conditions such as encephalomyletis are provided herein. The synthetic peptides and peptide copolymers as disclosed are obtained by substitution of at least one alpha amino acid by beta amino acid and/or ?3-homo amino acid.Type: ApplicationFiled: May 3, 2012Publication date: November 27, 2014Applicant: NATIONAL INSTITUTE OF IMMUNOLOGYInventors: Avadhesha Surolia, Ravi Kant Gautam, Vishnu Kumar Dwivedi, Sarika Gupta
-
Publication number: 20140349945Abstract: A PEG-oligopeptide-irinotecan conjugate has the general formula (I) (shown below) and a pharmaceutical composition containing the conjugate are disclosed. In the conjugate, PEG represents polyethylene glycol with a molecular weight of 300-60,000 Daltons; (AA)i represents an oligopeptide, AA represents the same or different amino acids in the oligopeptide; i is an integer of 2-12 representing the number of amino acids in the oligopeptide; j is an integer of 2-12 representing the number of irinotecan connected with the oligopeptide. In the conjugate, each terminal group of PEG can link with multiple irinotecans through oligopeptides, thereby greatly increasing the drug-loading capacity. Modification of the hydrophilic polymer can provide protection for the irinotecan, thereby improving drug absorption, prolonging the action time, enhancing the efficacy, reducing the dose and avoiding the toxic and side-effects.Type: ApplicationFiled: November 7, 2012Publication date: November 27, 2014Applicants: JENKEM TECHNOLOGYCO., LTD.. (TIANJIN), JENKEM TECHNOLOGY CO., LTD(BEIJING)Inventors: Lihua Xu, Wenzhe Huang, Xuan Zhao
-
Publication number: 20140350218Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: April 15, 2014Publication date: November 27, 2014Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: MAREN WATKINS, BALDOMERO M. OLIVERA, DAVID R. HILLYARD, J. MICHAEL MCINTOSH
-
Publication number: 20140349920Abstract: N-acylpeptide derivatives are described. Compositions comprising N-acylpeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with tumors or cancers, immune, nervous, vascular, musculoskeletal, cutaneous system, or other tissues or systems in a subject.Type: ApplicationFiled: January 3, 2013Publication date: November 27, 2014Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 8895514Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.Type: GrantFiled: March 15, 2013Date of Patent: November 25, 2014Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffan Walter, Harpreet Singh
-
Patent number: 8895697Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.Type: GrantFiled: September 9, 2010Date of Patent: November 25, 2014Assignee: Natimab Therapeutics S.r.l.Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
-
Patent number: 8895505Abstract: Provided is a method of treating type 2 diabetes in a subject, comprising administering a polypeptide comprising thymosin, or an active fragment or variant thereof, preferably comprising or consisting of the peptide LKKTETQ (SEQ ID NO: 1).Type: GrantFiled: November 10, 2010Date of Patent: November 25, 2014Assignee: AdiStem Ltd.Inventors: Vasilis Paspaliaris, James Thornton
-
Patent number: 8895695Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12, 14 or 18 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Gly, NMeGly, Pro or Pip, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have CXCR4 antagonizing properties. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: GrantFiled: July 1, 2010Date of Patent: November 25, 2014Assignees: Polyphor Ltd., Universität ZürichInventors: Jürg Zumbrunn, Steven J. Demarco, Sergio Lociuro, Jan Wim Vrijbloed, Frank Gombert, Reshmi Mukherjee, Kerstin Moehle, Daniel Obrecht, John Anthony Robinson, Heiko Henze, Barbara Romagnoli, Christian Ludin
-
Publication number: 20140341932Abstract: The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.Type: ApplicationFiled: May 14, 2014Publication date: November 20, 2014Inventors: Anthony Robert Milnes Coates, Peter Tormay, Andrew Lightfoot
-
Publication number: 20140342992Abstract: The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleotide-based theraputics, such as polynucleotides, oligonucleotides and peptide nucleic acids. A CPPs of the invention provides a balance between good cell entry efficency and low toxicity and comprises three contiguous domains: the central one being hydrophobic and the flanking ones consisting of arginine and aminohexanoic acid or beta-alanine residues. The hydrophobic domain contains a sequence selected from YQFLI, YRFLI, IQFLI and IRFLI.Type: ApplicationFiled: August 29, 2012Publication date: November 20, 2014Applicant: Medical Research CouncilInventors: Michael John Gait, Andrey Alexandrovich Arzumanov, Amer F. Saleh, Matthew J.A. Wood, Corinne Betts, Taeyoung Koo
-
Publication number: 20140342990Abstract: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.Type: ApplicationFiled: July 29, 2014Publication date: November 20, 2014Inventor: Ming Zhang
-
Publication number: 20140343249Abstract: A cell-killing peptide, more specifically a cell-killing CKP fusion peptide (CTD7:CKP) is disclosed, wherein a cell-killing peptide (CKP) comprising 10 amino acids in MTD of Noxa protein causing cell death, and 7 amino acids targeting a cancer cell are fused. The cell-killing CKP fusion peptide induces strong cell necrosis at various cancer cell lines (HeLa, HCT116, MCF-7, A549, BJAB, CT26, PC3 and the like) and shows strong tumor regression effect at a mouse tumor model using experimental animals, but does not show apoptosis at normal cells. Therefore, it can be broadly used to human body for treating various diseases requiring cell death, particularly, as an anti-cancer drug.Type: ApplicationFiled: December 15, 2011Publication date: November 20, 2014Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITYInventors: Tae-Hyoung Kim, Ae Ran Moon, Ji Young Kim
-
Publication number: 20140342983Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.Type: ApplicationFiled: April 28, 2014Publication date: November 20, 2014Inventors: Marina D'Angelo, Abdulhafez Selim
-
Patent number: 8889631Abstract: A delivery system for introducing a cargo molecule into cytosol of a living cell can include: a first membrane binding element linked to an endosomal compartment disrupting element through a first linker having one or more anionic moieties; and a second membrane binding element linked to an exogenous cargo molecule through a second linker having one or more anionic moieties, the second linker having a region that is selectively cleavable, wherein the first and second membrane binding elements both induce endocytosis into an early/recycling endosome and the endosomal compartment disrupting element destabilizes the early/recycling endosome such that the exogenous cargo molecule is released from the second membrane binding element and into the cytosol of the living cell.Type: GrantFiled: August 18, 2009Date of Patent: November 18, 2014Assignee: The University of KansasInventor: Blake R. Peterson
-
Patent number: 8889632Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.Type: GrantFiled: January 31, 2008Date of Patent: November 18, 2014Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Susan Korsmeyer
-
Patent number: 8889597Abstract: The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an army comprising the nucleic acids and peptides of the invention.Type: GrantFiled: January 30, 2009Date of Patent: November 18, 2014Assignee: Washington UniversityInventors: Nigel J. Cairns, Robert H Baloh, Alan Pestronk, Michael A. Gitcho, Alison M. Goate
-
Publication number: 20140335092Abstract: The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.Type: ApplicationFiled: May 15, 2014Publication date: November 13, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. SPELLBERG, Lin LIN, Ashraf IBRAHIM, Guanpingsheng LUO
-
Publication number: 20140336119Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.Type: ApplicationFiled: September 7, 2012Publication date: November 13, 2014Applicant: INSTITUT PASTEURInventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
-
Publication number: 20140335117Abstract: The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.Type: ApplicationFiled: October 5, 2012Publication date: November 13, 2014Inventors: Mogens Ryttergaard Duch, Shervin Bahrami
-
Publication number: 20140336105Abstract: Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating IgE-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis.Type: ApplicationFiled: July 3, 2014Publication date: November 13, 2014Inventors: Yechiel Shai, Avner Fink, Shay Yaari, Tova Waks, Zelig Eshhar, Christopher J. Arnush
-
Publication number: 20140335189Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Patent number: 8883964Abstract: The invention provides modified collagen and related therapeutic and diagnostic methods.Type: GrantFiled: September 6, 2012Date of Patent: November 11, 2014Assignee: The Johns Hopkins UniversityInventors: Michael Yu, Jennifer H. Elisseeff, Allen Yi-Lan Wang, Hyeseung Janice Lee, Xiao Mo
-
Patent number: 8884214Abstract: Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry, and novel halogenated peptides useful for the same, are disclosed. In particular, methods of using halogenated peptides as internal standards in proteomic analyzes, as well as methods of using halogenated peptides to conduct quality control assessments of and/or to calibrate liquid chromatography-mass spectrometry systems are disclosed.Type: GrantFiled: December 4, 2012Date of Patent: November 11, 2014Assignee: Institute for Systems BiologyInventors: Hamid Mirzaei, Rudolf Aebersold
-
Patent number: 8883740Abstract: Compositions for regenerating tissue and wound repair, among other applications, are described.Type: GrantFiled: January 22, 2009Date of Patent: November 11, 2014Assignees: Fundacao de Amparoa Pesquisa do Estado de Sao Paulo-Fapesp, Biolab Sanus Farmaceutica Ltda.Inventors: Janaina De Souza Ventura, Linda Christian Carrijo Carvalho, Ana Marisa Chudzinski-Tavassi
-
Patent number: 8883450Abstract: A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I): (X1)iX2X3X4SX5X6X7, wherein: X1 is a peptide containing from 3 to 6 amino acids, i equal to 0 or 1, X2 is a peptide containing from 3 to 9 hydrophobic amino acids, X3 is a peptide containing from 3 to 5 amino acids, the peptide including at least 3 contiguous or non-contiguous leucines X4 is a peptide containing from 2 to 5 amino acids chosen from Ala, Thr, Ser, Gln, Ile, Met, X5 is Ala or Val, X6 is Gln, Asn or His, X7 is Ala or Cys, provided that when the signal peptide originates from a natural precursor of a specific protein, the polypeptide of interest is different from the protein.Type: GrantFiled: March 17, 2011Date of Patent: November 11, 2014Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventor: Alexandre Fontayne
-
Publication number: 20140328831Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.Type: ApplicationFiled: March 24, 2014Publication date: November 6, 2014Inventors: William D. Carlson, Peter C. Keck
-
Publication number: 20140329759Abstract: The present invention involves the pharmaceutical field, including integrin antagonists, which have the capacities of inhibiting angiogenesis of tumors, binding integrin. These antagonists are a kind of polypeptide, which was modified by polyethylene glycol and after modification, it can be used to treat tumors. The sequence and structure of these antagonists is mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp, which demonstrates it is scientific, reasonable and feasible in tumor treatment and greatly expands the treatment spectrum. It can provide new ideas and perspectives for drug development and has significant social and market value.Type: ApplicationFiled: November 17, 2012Publication date: November 6, 2014Inventor: Hanmei XU
-
Publication number: 20140329739Abstract: Disclosed are an antibiotic peptide and the like, having an amino acid sequence of Ac-Phe-Lys-Lys-Leu-Lys-Lys-Leu-Phe-Ser-Lys-Leu-Trp-Asn-Trp-Lys-NH2 (SEQ ID No:1). Also disclosed are a method of preparing the antibiotic peptide and the like, and the application thereof. The antibiotic peptide and the like synthesized by the solid phase synthetic technology according to the present invention can be used as a formulation against microbial infection and as alternate or adjuvant medicaments of antibiotics in the prior art.Type: ApplicationFiled: January 17, 2012Publication date: November 6, 2014Applicant: JIANGSU PROTELIGHT PHARMACEUTICAL & BIOTECHNOLOGY CO., LTD.Inventors: Yuxin Chen, Mingxia Chen, Yibing Huang, Yang Li, Yong Wang, Lili Qu, Wenren Wang
-
Publication number: 20140329753Abstract: This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.Type: ApplicationFiled: May 2, 2013Publication date: November 6, 2014Inventor: JESSE MICHAEL JAYNES
-
Publication number: 20140329738Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.Type: ApplicationFiled: March 28, 2014Publication date: November 6, 2014Inventors: Kunwar Shailubhai, Gary S. Jacob
-
Publication number: 20140329761Abstract: The present invention relates generally to methods for the prevention and treatment of acute inflammatory conditions in individuals using an agonist of the complement C3a receptor.Type: ApplicationFiled: June 20, 2012Publication date: November 6, 2014Applicant: The University of QueenslandInventors: Trent Martin Woodruff, Stephen Maxwell Taylor
-
Publication number: 20140329737Abstract: The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like. Additionally, the improved MTD can be very useful in development of new drugs and incrementally modified drugs as uses of the improved MTD are possible in drug delivery systems, recombinant protein vaccines or DNA/RNA therapeutic agents, gene or protein therapies, and pharmacologically or medically useful protein production or medical, pharmacological and pharmaceutical compositions.Type: ApplicationFiled: November 23, 2012Publication date: November 6, 2014Applicant: Procell Therapeutics Inc.Inventors: Ki Deok Shin, Kang Jin Lee, Sunny Lim, Byung Kyu Lee, Jong Rae Kim
-
Publication number: 20140328868Abstract: A first or second polypeptide for use in a method of treating or preventing a disorder by tolerisation, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class II-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterised by an inappropriate immune response to the protein allergen from which the second polypeptide derives.Type: ApplicationFiled: May 2, 2014Publication date: November 6, 2014Inventors: Mark LARCHE, Roderick Peter HAFNER, Paul LAIDLER
-
Patent number: 8877738Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections.Type: GrantFiled: August 5, 2010Date of Patent: November 4, 2014Assignee: Spiderbiotech S.r.L.Inventors: Andrea Giuliani, Giovanna Pirri, Lorena Pizzuto, Santo Landolfo, Giorgio Gribaudo, David Lembo, Davide Gibellini
-
Patent number: 8877889Abstract: The present invention provides a tumor cell-killing peptide and a pharmaceutical composition for treating a cancer. The tumor cell-killing peptide of the present invention selectively homes into tumor cells so that it can induce the death of tumor cells effectively while minimizing the harming of normal cell.Type: GrantFiled: August 16, 2010Date of Patent: November 4, 2014Assignee: Industry-Academic Cooperation Foundation, Chosun UniversityInventor: Tae-Hyoung Kim
-
Publication number: 20140322279Abstract: The invention relates to a novel class of self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. The invention also encompasses methods for tissue regeneration, increasing the production of extracellular matrix proteins, and methods of treatment comprising administering self-assembling peptides.Type: ApplicationFiled: April 28, 2014Publication date: October 30, 2014Applicant: Massachusetts Institute of TechnologyInventors: Yoshiyuki Kumada, Shuguang Zhang